ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

This international study (ARON-3) collects real-world data on men with advanced prostate cancer receiving two types of treatment: hormone therapy combinations (including apalutamide, enzalutamide, abiraterone, or docetaxel) or lutetium-177 PSMA therapy (a targeted radioactive treatment). The goal is to understand outcomes and safety in a real-world setting. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with prostate cancer, confirmed by biopsy or imaging showing metastatic disease - You are receiving one of the specified hormone therapy combinations (ARON-3S group) OR lutetium-177 PSMA therapy (ARON-3Lu group) **You may NOT be eligible if...** - You have not been diagnosed with metastatic prostate cancer - You are not receiving one of the specified treatment regimens - You are under 18 years old Talk to your doctor to see if this trial is right for you.